Does a vaccination pay off to the state, insurance company and people?
One of the main activities of Metal-Aliance health insurance company (from now on referred to as M-A) was supporting prevention fund. M-A wanted to rationalize its support and thus asked about the prevention’s efficiency in terms of both social and economical measures. The objectives of this study were to find whether vaccination can be reasonably rationalized on both individual level and from the perspective of the health insurance company and also from the perspective of state.
For the analysis internal data of M-A was used; further e.g. MPSV data, professional studies and articles. Considering the dimension of our task we had to take into account:
The analysis therefore was not usual static processing of data. It involved analysis of many professional studies and, what is more, dealing with such an abstract term as year of quality life. For the purpose of our analysis, usual valuation of a year of quality life, i.e. CZK 1 million, was used.
The analysis brought clear answer that all of the vaccinations we focused on (except from papillomavirus) pay off to the state. Accounting for health and social insurance and taxes, state profits on each vaccinated citizen from CZK 300 to CZK 6 000. Most of the vaccinations also pay off from the individuals’ perspective.
Based on the results we were able to recommend M-A to carry on its set strategy and only consider the case of papillomavirus vaccination.